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Iron regulatory proteins (IRPs) regulate the expression of genes involved in ironmetabolism
by binding to RNA stem-loop structures known as iron responsive elements (IREs) in
target mRNAs. IRP binding inhibits the translation of mRNAs that contain an IRE in the
5′untranslated region of the transcripts, and increases the stability of mRNAs that contain
IREs in the 3′untranslated region of transcripts. By these mechanisms, IRPs increase
cellular iron absorption and decrease storage and export of iron to maintain an optimal
intracellular iron balance. There are two members of the mammalian IRP protein family,
IRP1 and IRP2, and they have redundant functions as evidenced by the embryonic lethality
of the mice that completely lack IRP expression (Irp1−/−/Irp2−/− mice), which contrasts
with the fact that Irp1−/− and Irp2−/− mice are viable. In addition, Irp2−/− mice also
display neurodegenerative symptoms and microcytic hypochromic anemia, suggesting
that IRP2 function predominates in the nervous system and erythropoietic homeostasis.
Though the physiological signiﬁcance of IRP1 had been unclear since Irp1−/− animals
were ﬁrst assessed in the early 1990s, recent studies indicate that IRP1 plays an essential
function in orchestrating the balance between erythropoiesis and bodily iron homeostasis.
Additionally, Irp1−/− mice develop pulmonary hypertension, and they experience sudden
death when maintained on an iron-deﬁcient diet, indicating that IRP1 has a critical role in
the pulmonary and cardiovascular systems. This review summarizes recent progress that
has been made in understanding the physiological roles of IRP1 and IRP2, and further
discusses the implications for clinical research on patients with idiopathic polycythemia,
pulmonary hypertension, and neurodegeneration.
Keywords: iron regulatory protein, iron responsive element, erythropoiesis, polycythemia, pulmonary hyperten-
sion, iron metabolism
INTRODUCTION
Iron is an indispensable element for all living organisms. Healthy
adults contain 4–5 g of iron, about 65% of which is contained
in hemoglobin where it participates in oxygen transport, 30–35%
is stored in liver, primarily in the storage protein, ferritin, and
1–2% is found in the form of iron–sulfur clusters or heme in
the catalytic centers of numerous essential enzymes and multi-
protein complexes such as the mitochondrial respiratory chain
complexes, which contain twelve iron–sulfur clusters and seven
hemes (Hentze et al., 2004; Darshan et al., 2010; Ganz andNemeth,
2012b; Rouault, 2013). Due to the essential role of iron in vivo, iron
deﬁciency can retard early development and impair cognitive abil-
ity of children, and iron deﬁciency anemia is a common nutrient
deﬁciency disease worldwide. Conversely, because of the chemi-
cal reactivity of iron and its ability through Fenton chemistry to
generate reactive hydroxyl radicals, which can then oxidize lipids,
proteins andDNA, iron overload can damage cells and tissues, and
lead to adverse consequences, such as those seen in hemochro-
matosis and hemolytic anemias. Therefore iron concentration has
to be tightly regulated in the tissues and cells of organisms in vivo.
Mammals have developed sophisticated mechanisms to
maintain appropriate iron concentrations in vivo. Thanks to
the application of genetic screens and transgenic technology
in biomedical research, our understanding of iron homeosta-
sis regulation has advanced signiﬁcantly in the last 15 years.
Iron homeostasis in mammals is mainly regulated by a set
of interlocking regulatory systems, including: (i) Hepcidin–
ferroportin (FPN1) mediated regulation of serum iron levels,
(ii) iron regulatory proteins (IRPs)/iron responsive element
(IRE) mediated regulation of intracellular iron homeostasis,
(iii) hypoxia inducible factor-2α (HIF2α) mediated transcrip-
tional regulation. These mechanisms regulate iron homeosta-
sis at different levels, and the interaction and cooperation of
these mechanisms ﬁne-tunes iron levels in vivo. The IRP/IRE
machinery post-transcriptionally regulates the expression of
target genes according to cellular iron status, providing the
fundamental regulation of iron homeostasis at the cellular
level. Recently, studies in animal models have also shown
that IRPs contribute signiﬁcantly to systemic iron homeosta-
sis and regulation of erythropoiesis. This review will begin
with an overview of mammalian iron homeostasis, and will
then focus on the more recent progress made in understand-
ing the roles of IRP1 and IRP2 in cellular and systemic iron
homeostasis.
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OVERVIEW OF SYSTEMIC AND CELLULAR IRON
METABOLISM
For a healthy adult, about 25–30 mg of iron is needed daily
for protein synthesis and cellular regeneration. To meet these
requirements, about 90% of iron is acquired from the recy-
cle of senescent red blood cells (RBC) by splenic macrophages,
whereas the remaining 10% is absorbed from the diet to com-
pensate for iron loss caused by bleeding, urinary excretion, and
sloughing of epithelial and mucous cells (Rigby, 1971). More
than 90% of daily iron consumption is used for RBC production
in erythropoietic tissues, and the most prominent manifestation
of iron deﬁciency is microcytic anemia (Rigby, 1971). The sys-
temic iron homeostasis is mainly maintained by coordinating iron
absorption through the duodenum, iron recycling through splenic
macrophages, iron utilization in bone marrow by erythropoiesis,
and iron storage in the liver. Because there is no known regulated
iron excretion pathway, regulation of intestinal iron absorp-
tion plays an important role in maintenance of systemic iron
homeostasis.
Mammals can absorb both heme iron and non-heme iron. Iron
derived from heme, especially in the people of western societies, is
estimated to contribute two thirds of the daily dietary iron absorp-
tion (West and Oates, 2008). However, the mechanism for heme
absorption is not yet clear. In the last decade, several heme trans-
porters have been identiﬁed, including heme carrier protein-1
(HCP1; Qiu et al., 2006; Laftah et al., 2009), HRG-1 (Rajagopal
et al., 2008; White et al., 2013), and FLVCR1 and 2 (Quigley et al.,
2004; Keel et al., 2008; Duffy et al., 2010), but their signiﬁcance in
intestinal iron absorption remains to be elucidated. For non-heme
iron absorption, ferric iron [Fe(III)] in the diet must be reduced
by a ferrireductase duodenal cytochrome b561 (Dcytb) to fer-
rous iron [Fe(II)] before the divalent metal transporter 1 (DMT1,
also known as DCT1 or NRAMP2) can transport iron across the
apical membrane into the cytosol of duodenal epithelial cells (so-
called enterocytes; Gunshin et al., 1997; McKie et al., 2001). Once
inside the cells, part of the newly absorbed iron is exported across
the basolateral membrane by the iron export protein, ferroportin
(FPN1, also known as MTP1 or IREG1) into circulating blood,
where Fe(II) is converted to Fe(III) by a membrane-bound fer-
roxidase, hephaestin (HEPH), before binding to transferrin and
circulating in blood to tissues and cells where iron is needed
(Abboud and Haile, 2000; Donovan et al., 2000; McKie et al.,
2000); enterocytes may use part of the iron absorbed for their
own metabolic needs, whereas excess iron can be sequestered in
ferritin for detoxiﬁcation and storage, and sloughing of these cells
at the end of their 3–4 days life span results in excretion of excess
duodenal iron (Potten, 1998).
Because of the essential role of duodenal iron absorption in
systemic iron homeostasis, duodenal uptake and transfer of iron is
regulated bymultiplemechanisms. HIF2αhas been shown to tran-
scriptionally regulate the expression of iron transporters in iron
deﬁciency and anemia conditions (Majmundar et al., 2010; Shah
and Xie, 2013). There are hypoxia responsive elements (HREs)
in the promoters of FPN1, DMT1, and DCYTB (also known as
CYBRD1) and the physiological importance of these HRE–HIF
interactions has been demonstrated in the duodenum of Hif2α
conditional knockout mice, where expression of FPN1, DMT1,
and DCYTB does not increase in response to iron deﬁciency,
suggesting that HIF2α has an important physiological role in tran-
scriptional regulation of iron homeostasis (Mastrogiannaki et al.,
2009; Shah et al., 2009). Secondly, hepcidin regulates the expres-
sion of FPN1 on the basolateral membrane of enterocytes and
thereby adjusts iron export from enterocytes into blood (Ganz
and Nemeth, 2011, 2012a). Hepcidin is a systemic iron regulatory
hormone that is secreted mainly by the liver. Circulating hepcidin
can bind FPN1 on the plasma membrane and induce its ubiq-
uitination, internalization and degradation, and thereby reduce
iron inﬂux into blood in a feedback manner (Nemeth et al., 2004).
Dysregulation of the hepcidin-FPN1 interaction causes the sys-
temic iron overload disease, hemochromatosis, which highlights
its signiﬁcance in systemic iron homeostasis. Thirdly, the intra-
cellular IRP/IRE machinery also regulates duodenal iron absorp-
tion, and IRP-related regulation will be discussed later in this
review.
Unlike intestinal epithelial cells, other cells in vivo use holo-
transferrin (transferrin bearing two ferric iron) as the major
iron source, and cells absorb iron through the transferrin
(Tf)/transferrin receptor (TfR1) cycle. Holo-transferrin in the cir-
culation binds to TfR1 on plasma membranes to form TfR1/Tf/Fe
complexeswhich then internalize to endosomes,whereupon acidi-
ﬁcationof endosomes induces the release of Fe(III) fromTf. Fe(III)
undergoes reduction to Fe(II) by the endosomal ferrireductase
STEAP3 before being transported by DMT1 across endosomal
membranes into cytosol (Fleming et al., 1998; Ohgami et al.,
2005). DMT1 may also directly transport non-transferrin-bound
iron (NTBI) into cells in vivo, especially in conditions including
hemochromatosis and hemolytic anemia when serum iron con-
centrations exceed the binding ability of transferrin, and therefore
NTBI accumulates (Sarkar, 1970; Chua et al., 2004). Once inside
the cytosol, part of the iron is taken up by mitochondria and
used for heme and iron–sulfur cluster synthesis; excess iron can
be exported out of the cells by the iron exporter FPN1, and much
extra iron is sequestered in ferritin for detoxiﬁcation and storage.
Ferritin can store up to 4500 iron atoms in a spherical structure
formed by 24 subunits of H- and L- ferritin, which self-organize
in different ratios, depending on the tissue (Theil, 2012). The
IRP/IRE machinery coordinates cellular iron absorption, export,
utilization and storage, and thereby regulates intracellular iron
homeostasis
REGULATION OF INTRACELLULAR IRON HOMEOSTASIS BY
THE IRP/IRE MACHINERY
The IRP/IRE machinery registers intracellular iron levels, and
coordinates iron absorption, export, utilization and storage, pro-
viding the fundamental machinery for regulation of intracellular
iron metabolism (Rouault, 2006, 2013; Wallander et al., 2006;
Muckenthaler et al., 2008). The IRE is a conserved stem-loop
structure in the untranslated region (UTR) of target mRNAs. A
typical loop has six nucleotides with the sequence of CAGUGN,
in which the ﬁrst C and the ﬁfth G are believed to form a
base-pair that stabilizes the structure (Sanchez et al., 2011). The
six-nucleotide loop is connected to a stem that is separated
into an upper and lower part by an unpaired bulge C residue
that divides the stem in the middle. IRE sequences are highly
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conserved, and mutations of the IRE can cause iron dysregulation
and diseases, suggesting a signiﬁcant role of IRP/IRE regulation
in iron homeostasis (Kato et al., 2001; Ismail et al., 2006). IREs
are recognized and bound by IRP proteins, but the effect of
IRP binding depends on the position of the IRE in the mRNA
targets. If an IRE is located in the 5′UTR of target mRNAs,
IRP binding can inhibit the translation of such target mRNAs,
including L- and H-ferritin (iron storage protein) (Theil, 1990),
FPN1 (iron export protein; Abboud and Haile, 2000; Donovan
et al., 2000; McKie et al., 2000), erythroid 5-aminolevulinate syn-
thase (eALAS or ALAS2, the ﬁrst enzyme for heme synthesis;
Dandekar et al., 1991), mitochondrial aconitase (ACO2, energy
production; Kim et al., 1996; Schalinske et al., 1998), HIF2α
(erythropoiesis and hypoxia response; Sanchez et al., 2007), and
Drosophila succinate dehydrogenase (SDH, citric acid cycle and
mitochondrial electron transport chain; Kohler et al., 1995; Mele-
fors, 1996). Conversely, if IREs are present in the 3′UTR of
target mRNAs, IRP binding can increase their expression by sta-
bilizing the mRNAs that include TfR1 and DMT1 (iron import
proteins; Garrick et al., 2003). In summary, when activated by
iron deﬁciency, IRPs bind the IREs of target mRNAs to increase
iron absorption and decrease iron export, iron utilization and
iron storage, thereby maintaining appropriate intracellular iron
concentrations.
IRON REGULATORY PROTEINS
Iron regulatory proteins are soluble cytosolic proteins that alter
their activities according to intracellular iron levels. There are two
IRP proteins in mammalian cells, IRP1 and IRP2, which share
56% sequence identity. In addition, IRP2 has a cysteine-rich 73
amino acid insertion in its N-terminal, but the function of the
insertion is not clear yet (Pantopoulos, 2004). Both IRP1 and
IRP2 are ubiquitously expressed, with IRP1 highly expressed in
the kidneys, liver and brown fat, and IRP2 highly expressed in
the central nervous system (Meyron-Holtz et al., 2004). IRP1 and
IRP2 are regulated by differentmechanisms. IRP1 is a bifunctional
enzyme. In iron-replete conditions, IRP1 acquires a [4Fe–4S] clus-
ter in its active cleft and displays cytosolic aconitase activity that
catalyzes the conversion of citrate and isocitrate in the cytosol,
which probably enhances NADPH generation and lipid synthe-
sis (Tong and Rouault, 2007). In iron-deﬁcient conditions, IRP1
loses its iron–sulfur cluster and acquires IRE-binding activity.
The iron–sulfur cluster functions as the iron sensor of IRP1 that
endows the protein with the ability to register intracellular iron
concentration and adjust its activity accordingly (Rouault, 2006;
Medenbach et al., 2011). In contrast to the bifunctional enzyme
activity of IRP1, IRP2 does not have an iron–sulfur cluster and
lacks aconitase activity, and its activity is regulated by ubiquiti-
nation and proteasomal degradation (Rouault, 2009; Salahudeen
et al., 2009; Vashisht et al., 2009). Evidence from two indepen-
dent groups demonstrated that IRP2 is targeted for proteasomal
degradation by an E3 ubiquitin ligase complex that contains an
F-box protein, FBXL5 (Salahudeen et al., 2009; Vashisht et al.,
2009). FBXL5 has a hemerythrin domain that likely binds iron
and oxygen, enabling it to function as a regulatory switch that
determines the stability of FBXL5, and consequently regulates
E3 ubiquitin ligase activity (Chollangi et al., 2012). In brief, iron
deﬁciency and hypoxia destabilize FBXL5 protein, decrease the
activity of the E3 ubiquitin ligase, and thereby increase IRP2 activ-
ity. Fbxl5−/− mice were embryonic lethal, and the lethality could
be rescued by deletion of Irp2, suggesting that the lethality is likely
caused by augmented expression of IRP2 protein, a result that
underscores the essential role of FBXL5-E3 ubiquitin ligase in reg-
ulation of IRP2 expression (Moroishi et al., 2011). IRP1 is also
a target of the FBXL5-E3 ubiquitin ligase complex, and after it
loses its [4Fe-4S] cluster by mutation of three cystine residues,
IRP1 is down-regulated likely by the FBXL5-mediated proteaso-
mal degradation pathway (Salahudeen et al., 2009; Vashisht et al.,
2009). Because IRP1 is relatively stable in the cytosolic aconitase
form at iron-replete conditions when FBXL5-E3 ubiquitin ligase is
active, the physiological signiﬁcance of the FBXL5-mediated pro-
teasomal degradation pathway on IRP1 expression is still elusive
(Recalcati et al., 2006).
PHYSIOLOGICAL SIGNIFICANCE OF IRP1 AND IRP2
The IRP/IRE machinery maintains intracellular iron homeostasis
and plays a crucial role in development and normal physiol-
ogy. Animals bred to lack both alleles of Irp1 and Irp2 are not
viable, and further analyses have shown that embryos at the
blastocyst stage display brown color and abnormal morpholo-
gies, supporting an essential role of IRPs in early development,
before implantation of the embryo (Smith et al., 2006). In con-
trast, mice with either Irp1 or Irp2 deﬁciency are viable and
fertile, suggesting that Irp proteins can compensate for the loss
of one another and are functionally redundant (Meyron-Holtz
et al., 2004). The essential role of Irp proteins is also highlighted
by conditional knockout experiments which have shown that lack
of Irp1 and Irp2 in the intestine of mice results in early death
at around 4 weeks of age likely due to intestinal malabsorp-
tion and dehydration, and lack of Irp1 and Irp2 in hepatocytes
causes liver failure and death of animals within 12 days post-
partum (Galy et al., 2008, 2010). Conditional deletion of both
Irp1 and Irp2 in hepatocytes compromises iron–sulfur cluster and
heme synthesis, and impairs mitochondrial functions, suggest-
ing an essential role of Irps in supplying iron to mitochondria
to maintain respiration. Though adult mice with ligand-induced
deletion of both Irp1 and Irp2 in duodenal enterocytes responded
well to iron loading and erythropoietic stimulation, these mice
displayed reduced iron absorption and iron accumulation in duo-
denal enterocytes, suggesting that Irps play an important role in
adjusting duodenal iron absorption by regulating ferritin expres-
sion to create a ferritin dependent “mucosal block” (Galy et al.,
2013).
PHYSIOLOGICAL SIGNIFICANCE OF IRP2
Though deletion of both Irp1 and Irp2 is embryonic lethal, mice
with deletion of either Irp1 or Irp2 are viable and fertile (Meyron-
Holtz et al., 2004). Irp2 deﬁciency causes iron misregulation in
the duodenum, central nervous system, and most prominently
in motor neurons of spinal cord; misregulation is characterized
by increased expression of ferritin, decreased expression of TfR1,
and signiﬁcant iron accumulation in the duodenal mucosa and
neurons throughout the brain (LaVaute et al., 2001). Iron misreg-
ulation correlates with axonal degeneration and neuronal death in
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the brain and spinal cord, and animals in late stages of adult-
hood display a movement disorder characterized by abnormal
gait, tremor, and hind-limb paralysis (LaVaute et al., 2001; Jeong
et al., 2011). Compared with Irp2−/− mice, loss of one more
copy of Irp1 in Irp1+/−Irp2−/− mice exacerbates the neurode-
generative symptoms as evidenced by the increased myelin dense
bodies in the ventral spinal cord in the region where motor neu-
rons are found (a hallmark of neurodegeneration), increased stress
markers, increased macrophage inﬁltration, and decreased diam-
eters of motor neuronal axon bundles, suggesting that there is
a dosage effect of Irp1 and Irp2 deﬁciency and conﬁrming that
neurodegenerative symptoms of Irp2−/− mice are caused by iron
dysregulation. Deﬁciency of Irp2 increases the expression of the
iron storage protein ferritin and decreases expression of the iron
importer TfR1, leading to functional iron deﬁciency (lack of bio-
logically available iron) in conjunction with apparent ferric iron
overload caused by sequestration of iron in ferritin; and the
notion that there is functional iron deﬁciency is also supported
by deﬁciency of mitochondrial complex I/II activity (Figure 1;
Jeong et al., 2011). The neurodegenerative symptoms of Irp2−/−
mice were improved by activation of IRP1 activity with oral
treatment by Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-
oxyl), a scavenger of reactive oxygen species, which was shown
to destabilize the iron–sulfur cluster ligand of IRP1 and restore
its IRE-binding activity (Ghosh et al., 2008; Wilcox and Pearl-
man, 2008). The neurodegenerative symptoms of Irp2−/− mice
were also improved by deletion of one allele of ferritin-H chain,
which limited iron sequestration and increased intracellular iron
availability. These studies support that lack of IRE-binding activ-
ity of IRP2 and subsequent derepression of ferritin translation
cause the neurodegenerative diseases of Irps deﬁcient animals
(Ghosh et al., 2008; Jeong et al., 2011). The neurodegenerative
symptoms of Irp2−/− mice were also assessed by other two groups
in independent Irp2−/− mouse colonies. Compared with the neu-
rodegenerative symptoms characterized by ataxia, tremor and
motor impairment associatedwith iron deposit in thewhitematter
and nuclei throughout the brain in the Irp2−/− mice of our group
(LaVaute et al., 2001; Jeong et al., 2011), one group found that
while their Irp2−/− mice displayed discrete impairment of balance
and/or motor coordination, they did not ﬁnd iron deposit with
Perl’s-DAB iron staining and did not ﬁnd evidence of neuronal
degeneration in the brain (Galy et al., 2006); the other group found
that their Irp2−/− mice had signiﬁcant locomotor dysfunction and
increased iron deposits in the cortex, mid-brain and cerebellum
of Irp2−/− mice, but they did not ﬁnd cellular degeneration with
Fluoro-Jade staining (Zumbrennen et al., 2009). The locomotor
dysfunction displayed by these three Irp2−/− mouse colonies con-
ﬁrms the signiﬁcant role of Irp2 inmouseneuronal systemand also
suggests that the discrepancy is likely from either different mouse
genetic backgrounds or differences in experimental assessement,
but not due to off-target effects as was suggested before (Galy et al.,
2006). Since IRP1 and IRP2 have redundant functions, deletion
of one copy of Irp1 in Irp2−/− mice probably could exacerbate
the neurodegenerative symptoms and provide more information
of IRPs function in the other two Irp2−/− mouse colonies. Fur-
ther, conditional knockout of both Irp1 and Irp2 in neurons as
in hepatocytes and enterocytes could shed light on the role of
IRPs in neuronal system, although complete loss of Irps has been
lethal in several settings (Smith et al., 2006; Galy et al., 2008, 2010,
2013).
Irp2−/− mice also display microcytic hypochromic anemia
(Cooperman et al., 2005; Galy et al., 2005). Erythroblasts of
Irp2−/− mice have decreased TfR1 expression and iron levels, and
increased protoporphyrin IX levels, supporting an iron-limited
erythropoiesis model. Irp2 deﬁciency destabilizes TfR1 mRNA,
and lack of TfR1 protein causes iron deﬁciency and eventually
leads to microcytic anemia. The microcytic anemia of Irp2−/−
mice suggests that Irp2 plays a dominant role in regulating iron
homeostasis in erythroid cells (Figure 1). While the neurodegen-
erative symptoms of Irp2−/− are corrected by Tempol treatment,
the treatment didnot improve themicrocytic anemia (Ghosh et al.,
2008). Analogously, while Tempol treatment signiﬁcantly con-
verted Irp1 fraction from cytosolic aconitase form to IRE-binding
form in forebrain lysate, which likely compensated the loss of IRE-
binding activity in the brain of Irp2−/− mice, Tempol treatment
did not increase the IRE-binding activity of Irp1 in erythroblasts,
likely because Irp1 is already mainly in the IRE-binding form in
erythroblasts (Ghosh et al., 2008).
In addition to the microcytic anemia and neurodegenerative
symptoms, Irp2−/− mice displayed iron overload in duodenum
and liver, but interestingly, these animals also displayed iron deﬁ-
ciency in the spleen and bone marrow (Cooperman et al., 2005;
Galy et al., 2005). Conditional deletion of Irp2 in mouse duode-
nal enterocytes and liver hepatocytes repeats the iron overload
phenotype of duodenum and liver, suggesting that iron overload
in these two tissues is likely due to cell-autonomous functions
of Irp2 deﬁciency in enterocytes and hepatocytes (Ferring-Appel
et al., 2009). In contrast, conditional deletion of Irp2 in mouse
splenic macrophages did not produce the splenic iron deﬁciency
seen in Irp2−/− mice, suggesting that the splenic iron deﬁciency
of Irp2−/− mice is likely secondary to iron misregulation in other
cell types. Considering that (i) both spleen and bone marrow
macrophages of Irp2−/− mice display iron deﬁciency, (ii) both
spleen and bone marrow are erythropoietic tissues, (iii) splenic
macrophages play an essential role in recycling iron from senes-
cent RBC, the iron deﬁciency of splenic macrophages probably
results from reduced acquisition of iron from red cell turnover
in anemic Irp2−/− mice. Conditional deletion of Irp2 in ery-
throblasts might shed light on the pathogenesis of splenic iron
deﬁciency.
PHYSIOLOGICAL SIGNIFICANCE OF IRP1
Though both IRP1 and IRP2 are ubiquitously expressed and show
similar binding afﬁnities for target IREs in in vitro experiments,
Irp1−/− and Irp2−/− mice display different phenotypes (Hender-
son et al., 1993; Kimet al., 1995). Because theprotein levels and IRE
binding activities of IRP1 in electrophoresis mobility shift assays
are much higher than those of IRP2 in cultured cells and in certain
tissues such as liver and kidneys, the physiological signiﬁcance of
IRP1 has been relatively elusive. In contrast to the neurodegen-
eration and anemia symptoms of Irp2−/− mice, Irp1−/− mice
initially appeared asymptomatic and the physiological signiﬁcance
of IRP1 in iron metabolism was unclear. However, evidence from
Irp1−/− mice has recently emerged, which indicates that IRP1
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FIGURE 1 |The physiological effect of IRP2 deficiency in vivo. IRP2 is
the predominant IRP protein in erythroblasts and neurons. According to
intracellular iron status, IRP2 protein levels are regulated by the
FBXL5-dependent proteasomal degradation pathway. By binding to the
IREs in target transcripts of iron metabolism genes, IRP2 increases the
expression of iron importers TfR1 and DMT1, and decreases the
expression of the iron storage protein, ferritin, the iron exporter FPN1,
and some iron utilization-related genes including ACO2 and eALAS, as
well as other potential target genes, to maintain optimal intracellular
iron levels. In erythroblasts, IRP2 deﬁciency decreases the expression of
TfR1, resulting in insufﬁcient import of iron by the Tf/TfR1 cycle to
support heme biosynthesis, and derepresses eALAS expression, leading
to protoporphyrin IX accumulation and microcytic hypochromic anemia.
In neurons, IRP2 deﬁciency decreases the expression of the iron
importer TfR1 and increases the expression of the ferritin. The
accumulation of iron by ferritin depletes biologically available iron from
the cytosol and leads to functional iron deﬁciency, mitochondrial
dysfunction and neuronal degradation.
plays an essential role in regulation of systemic iron homeostasis
and erythropoiesis.
PHYSIOLOGICAL SIGNIFICANCE OF IRP1 IN ERYTHROPOIESIS AND
SYSTEMIC IRON HOMEOSTASIS
In contrast to Irp2−/− mice that developmicrocytic hypochromic
anemia with hematocrits of about 36%, adult Irp1−/− mice pro-
duce more RBCs than wild type animals (hematocrit ∼50 vs.
∼45%, Irp1−/− vs. wild type; Cooperman et al., 2005; Ghosh et al.,
2013). High hematocrits were also observed in 4–6 weeks oldmice
of adifferent colonywhere two research groups found that Irp1−/−
mice had hematocrits of more than 70% (Pawlus and Hu, 2013;
Wilkinson and Pantopoulos, 2013). However, these researchers
found that hematocrits of Irp1−/− mice decreased with age, and
the difference of hematocrits between Irp1−/− and wild typemice
disappeared after 8 weeks of age. We also checked the hematocrits
of Irp1−/− mice in different ages (from 4 weeks to 14 months
old), but did not ﬁnd a signiﬁcant decrease of the hematocrits of
mice older than 8 weeks of age (Zhang et al., unpublished data),
and the reason for the inconsistent observations is not yet clear.
More striking results are obtained from Irp1−/− mice that are
maintained on an iron-deﬁcient diet (Ghosh et al., 2013). In con-
trast to the general observation that iron deﬁciency causes iron
deﬁciency anemia, maintenance on an iron-deﬁcient diet signif-
icantly increased the hematocrits of Irp1−/− mice from about
50% to more than 60%. Serum erythropoietin (EPO) levels of
Irp1−/− mice were more than seven-fold higher than that in
wild type mice maintained on an iron-deﬁcient diet, and ani-
mals with these high EPO levels developed splenomegaly and
increased splenic erythropoiesis, supporting a model that there
is EPO-dependent extracellular erythropoiesis in Irp1−/− mice.
HIF2α is the master transcription factor in vivo that regulates
EPO levels and subsequent RBC production according to both
hypoxia and iron status (Semenza, 2009; Haase, 2013). HIF2α
mRNA has an IRE in its 5′UTR with an initially unknown sig-
niﬁcance (Sanchez et al., 2007). In the renal carcinoma cell line,
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786-O cells, HIF2α expression is increased by Irp1 knockdown
but not Irp2 knockdown, suggesting that Irp1 probably plays a
major function in repressing HIF2α translation by binding to its
5′IRE in these particular cells (Zimmer et al., 2008). Irp1 but not
Irp2 deﬁciency signiﬁcantly increased the percentage of HIF2α
mRNA found in the polysomal fractions of mouse kidneys and
liver, proving that Irp1 but not Irp2 represses HIF2αmRNA trans-
lation in cells of these two tissues in vivo (Anderson et al., 2013;
Wilkinson and Pantopoulos, 2013). Thus, in Irp1−/− mice, Irp1
deﬁciency derepresses HIF2α translation, which transcriptionally
increases EPO expression and subsequently drives red blood pro-
duction, leading to polycythemia as a consequence (Anderson
et al., 2013; Ghosh et al., 2013;Wilkinson and Pantopoulos, 2013).
Notably, Irp1−/− mice have severe iron deﬁciency as evidenced
by low serum iron levels and reduced stainable tissue iron com-
pared with wild type animals, which is likely caused by increased
erythropoiesis that channels iron into the production of red cells,
and consequently depletes Tf bound iron in blood and tissue iron
stores.
The polycythemia of Irp1−/− mice and its exacerbation by iron
deﬁciency suggest a crucial role of Irp1 in regulating systemic iron
levels and erythropoiesis (Figure 2). HIF2α is regulated at the post-
translational level by prolyl hydroxylases (PHDs) that use oxygen
and iron as substrates to hydroxylate HIF2α at two conserved
proline residues. Following hydroxylation,HIF2αundergoes ubiq-
uitination by the von Hippel–Lindau E3 ubiquitin ligase and is
subsequently degraded through the proteasomal pathway (Maj-
mundar et al., 2010; Lee and Percy, 2011; Yoon et al., 2011; Haase,
2013). Hence, HIF2α can sense hypoxia and iron deﬁciency, and
then increases EPO expression and drives red blood production,
a process that consumes large amounts of iron. The regulation
of HIF2α translation by Irp1 provides a safeguard that prevents
FIGURE 2 |The scheme of physiological significance of IRP1 in vivo.
IRP1 is the predominant IRP protein in renal interstitial ﬁbroblasts and
pulmonary endothelial cells. In iron-replete conditions, IRP1 ligates an
iron–sulfur cluster and displays cytosolic aconitase activity; in
iron-depleted conditions, IRP1 loses its iron–sulfur cluster and binds to
IREs of target mRNAs to regulate expression of iron metabolism related
genes. By binding to the 5′IRE of HIF2α mRNA, IRP1 regulates HIF2α
expression according to iron and oxygen status, and thereby ﬁne-tunes
the levels of HIF2α protein in cooperation with prolyl hydroxylases and
the Von Hippel–Lindau mediated proteasomal degradation pathway. In
hypoxia or iron deﬁciency conditions, HIF2α protein is stabilized due to
inactivation of prolyl hydroxylases, and then translocates to nucleus and
transcriptionally increase erythropoietin (EPO) expression. Circulating
through blood, EPO binds to EPO receptors on erythroblasts and
stimulates erythroblasts to produce red blood cells (RBC), a process
that consumes large amount of iron. When too much iron is consumed
and systemic iron levels are low, IRP1 will be activated to reduce
HIF2α expression and restrict RBC production. By this feedback
mechanism, IRP1 regulates the balance between systemic iron
homeostasis and erythropoiesis. In pulmonary endothelial cells, IRP1
regulates HIF2α translation and subsequently regulates the expression of
endothelin-1 (ET-1), a peptide hormone that regulates pulmonary vascular
contraction and the proliferation of smooth muscle cells,
cardiomyocytes, and ﬁbroblasts. Though the exact mechanism remains
to be elucidated, IRP1 deﬁciency causes pulmonary hypertension and
cardiovascular diseases in mice likely by derepression of HIF2α
expression, increase of ET-1 levels and most probably other HIF2α
targets also.
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erythropoiesis from consuming toomuch iron to deplete systemic
iron. While HIF2α senses hypoxia and stimulates EPO expression
and RBC production, Irp1 ﬁne-tunes HIF2α expression to ensure
that there is enough iron available for iron–sulfur cluster synthe-
sis; if intracellular iron levels are low, iron–sulfur cluster synthesis
is impaired and IRP1 will be converted to the IRE-binding form,
which represses HIF2α translation, and thereby decreases RBC
production to restore systemic iron balance (Figure 2). Irp1−/−
mice on an iron-deﬁcient diet have increased polycythemia, severe
iron deﬁciency, and sudden death due to peritoneal hemorrhage,
which emphasizes the crucial role of Irp1 in systemic iron home-
ostasis and erythropoiesis (Ghosh et al., 2013). Maintenance of
Irp1−/− animals in 10%oxygen for 3weeks can increase the hema-
tocrits of Irp1−/− mice to as high as 80%, compared to 65% in
wild type mice, highlighting the signiﬁcance of IRP1 in systemic
iron homeostasis and erythropoiesis under hypoxia (Zhang et al.,
unpublished data). Mice that inducibly express a constitutively
active IRP1 mutant (IRP1∗) develop macrocytic anemia, probably
due to impaired erythropoiesis as displayed by increased erythroid
progenitor and decreased numbers of mature cells (Casarrubea
et al., 2013). Erythroblasts of IRP1∗ mice have higher TfR1 expres-
sion compared to wild type animals, which could potentially cause
iron overload and impair normal erythropoiesis. In addition, high
levels of Irp1 are expected to repress HIF2α translation and subse-
quently reduce EPO levels and RBC production. The macrocytic
anemia of IRP1∗ highlights the importance of IRP/IRE balance in
iron and erythropoiesis homeostasis.
In addition to its function in the regulation of erythropoiesis
and systemic iron homeostasis, IRP1 probably also plays a role
in coordinating intracellular Fe-S cluster and heme synthesis in
erythroid cells (Wingert et al., 2005; Ye and Rouault, 2010; Chung
et al., 2014). Because IRP1 has a [4Fe-4S] cluster as the sensor to
adjust its IRE-binding activity, IRP1 can sense Fe-S cluster deﬁ-
ciency andpotentially repress the translation of ALAS2 (eALAS) by
binding to a IRE in its 5′UTR. As ALAS2 is the ﬁrst enzyme of the
heme synthesis pathway, translational repression by IRP proteins
can coordinate the synthesis of Fe-S clusters and heme (Dandekar
et al., 1991; Wingert et al., 2005; Chung et al., 2014). Deﬁciency of
glutaredoxin 5 (GLRX5), a scaffold protein required formitochon-
drial Fe-S cluster synthesis, activated IRP1, which inhibitedALAS2
translation and subsequently led to anemia in zebraﬁsh, suggest-
ing a role of IRP1 in coordinating Fe-S cluster and heme synthesis
(Wingert et al., 2005). Consistent with the zebraﬁsh studies, RNAi
knockdown of GLRX5 in K562 cells markedly reduced ALAS2
expression, and deﬁciency of GLRX5 in a patient caused by an
intronic mutation that caused missplicing signiﬁcantly increased
the IRE-binding activity of IRP1, and caused sideroblastic anemia
(Camaschella et al., 2007; Ye et al., 2010). IRP1 deﬁciency sig-
niﬁcantly increased protoporphyrin levels in erythroid cells with
heterozygous deﬁciency of mitoferrin1, the major mitochondrial
iron importer in erythroid cells, also suggesting that IRP1 is an
important link between Fe-S cluster and heme synthesis (Shaw
et al., 2006; Chung et al., 2014). The evidence suggests that IRP1
likely plays an important role in orchestrating the heme and Fe-
S cluster synthesis in erythroid precursors; however, the role of
IRP2 was not really tested, considering that: (1) Zebraﬁsh do not
have an IRP2 homolog (Wingert et al., 2005); (2) The effect of
IRP2 deﬁciency on protoporphyrin levels in erythroid precursors
with heterozygousmitoferrin1 deﬁciency was not checked (Chung
et al., 2014); (3) IRP2 expression was also signiﬁcantly increased
in GLRX5 deﬁcient ﬁbroblasts (Ye et al., 2010); (4) Irp2−/− mice,
but not Irp1−/− mice, have increased protoporphyrin IX levels
(Coopermanet al.,2005). Thus, the roles of IRP1 and IRP2 in coor-
dinating heme and Fe-S cluster synthesis in erythroid precursors
may require further investigation.
PHYSIOLOGICAL SIGNIFICANCE OF IRP1 IN PULMONARY AND
CARDIOVASCULAR SYSTEM
In addition to the essential role of IRP1 in maintaining ery-
thropoiesis and systemic iron homeostasis, IRP1 also plays
an important role in pulmonary and cardiovascular system
(Figure 2). Irp1−/− mice displayed cardiac hypertrophy and pul-
monary hypertension, two severe human diseases with unclear
pathogenesis (Ghosh et al., 2013). HIF2α has been previously
implicated in the pathogenesis of pulmonary hypertension. Het-
erozygous deﬁciency of HIF2α protects mice against developing
pulmonary hypertension and right ventricular dysfunction during
prolonged hypoxia, suggesting that HIF2α is involved in patho-
genesis of pulmonary hypertension (Brusselmans et al., 2003).
Chuvash polycythemia is a hereditary disease caused byVHLR200W
mutation that disrupts the degradation pathway of HIFα and
consequently increases HIF2α protein to high levels (Hickey
et al., 2007). Chuvash polycythemia patients and a corresponding
mouse model with a VHLR200W mutation develop polycythemia
and pulmonary hypertension, and the pulmonary hypertension
of the mouse model is improved by deletion of one allele of
Hif2α, suggesting that there is a pathogenic role of HIF2α in
this disease (Bushuev et al., 2006; Hickey et al., 2010; Formenti
et al., 2011). Endothelin-1, a potent vasoconstrictor and HIF tar-
get, is signiﬁcantly increased in Chuvash mice and could be a
downstream effector molecule in the pathogenesis of pulmonary
hypertension (Bushuev et al., 2006; Hickey et al., 2010; Thorin and
Clozel, 2010; Shao et al., 2011). HIF2α expression is signiﬁcantly
increased in cultured primary endothelial cells of Irp1−/− mice,
and endothelin-1 expression is also signiﬁcantly increased in lung
tissues of Irp1−/− mice, supporting a pathogenic role of these
molecules in the pulmonary hypertension (Ghosh et al., 2013).
However, preliminary results of Irp1−/− micedidnot reveal signif-
icant pulmonary vascular remodeling, in contrast to the Chuvash
and the prolonged-hypoxia mouse models, and thus the mech-
anism underlying the pulmonary hypertension of Irp1−/− mice
is not very clear yet. Low iron treatment signiﬁcantly increases
EPO expression and exacerbates the polycythemia of Irp1−/−
mice, which could be attributed to the stabilization of HIF2α
by iron deﬁciency; in contrast, the iron-deﬁcient diet did not
exacerbate the pulmonary hypertension of Irp1−/− mice, and
the endothelin-1 levels were not altered either, suggesting that
there are mechanistic differences in the pathophysiology of poly-
cythemia and pulmonary hypertension. Analysis of the underlying
molecular pathophysiology could shed light on the pathogen-
esis of these diseases. The IRP1/HIF2α interaction in kidneys
represents a mechanism that protects systemic iron homeosta-
sis during erythropoiesis by preventing red cells production from
depleting systemic iron, whereas the evolutionary rationale for the
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IRP1/HIF2α interaction in pulmonary vascular function is not yet
clear (Figure 2).
Maintenance on an iron-deﬁcient diet also signiﬁcantly
decreases life span of Irp1−/− mice. From the age of 3months old,
Irp1−/− mice on the iron-deﬁcient diet are prone to sudden death
in which apparently healthy mice die without warning (Ghosh
et al., 2013). Pathological analyses of mouse carcasses revealed that
thesemice died of abdominal hemorrhage around the perinephric
area, suggesting that there is an essential role of IRP1 in the vascu-
lar system. Considering that the iron-deﬁcient diet exacerbates the
polycythemia of Irp1−/− mice by stimulating HIF2α expression,
HIF2α probably also plays a role in the peritoneal hemorrhage.
Notably, Chuvash polycythemia patients, who have high HIF2α
expression, also have increased incidence of thrombotic events,
major bleeding episodes, and premature mortality, suggesting
that there are probably similar mechanisms operating in Chuvash
polycythemia patients and the Irp1−/− mouse models (Gordeuk
and Prchal, 2006). Coagulation factor VIII (FVIII) is an essential
blood-clotting protein, and high levels of FVIII are reported to
associate with increased risk of deep vein thrombosis and pul-
monary embolism (Jenkins et al., 2012). An alternative transcript
variant 2 of FVIII has a potential 5′IRE that, if functional, could
derepress FVIII expression in IRP1 deﬁcient animals or patients
(Livesey et al., 2012). The expression and role of FVIII in the
phenotypes associated with the Irp1−/− mouse model warrant
investigation.
DIFFERENT PHENOTYPES OF Irp1−/− AND Irp2−/− MICE ARE
LIKELY CAUSED BY CELL-SPECIFIC EXPRESSION
The relative functions of IRP1 and IRP2 have been a subject
of debate since they were identiﬁed two decades ago. On one
hand, IRP1 and IRP2 are highly conserved in sequence and
displayed similar binding afﬁnity to their target in in vitro exper-
iments (Henderson et al., 1993; Kim et al., 1995); on the other
hand, IRP1 and IRP2 have different regulatory mechanisms
with IRP1 functioning as a bifunctional protein and IRP2 being
degraded through the proteasomal pathway. The polycythemia
and pulmonary hypertension phenotype of Irp1−/− mice and
the anemia and neurodegeneration phenotype of Irp2−/− mice
likely support a unique functions of IRP1 and IRP2 in ery-
thropoiesis/cardiovascular regulation and erythroblasts/nervous
system, respectively. However, a recent study, which analyzed the
endogenous transcripts bound in vitro by overexpressed IRP1 and
IRP2 proteins withmicroarray, showed that IRP1 and IRP2 shared
44 transcripts including the transcripts that had been conﬁrmed
in literature, i.e., FTL, FTH, TfR1, DMT1, FPN1, ACO2, eALAS,
and HIF2α (Sanchez et al., 2011). Derepression of the shared tar-
get HIF2α most likely causes the polycythemia and pulmonary
hypertension of Irp1−/− mice (Anderson et al., 2013; Ghosh et al.,
2013; Wilkinson and Pantopoulos, 2013), and dysregulation of
the shared targets ferritin, TfR1, and eALAS likely lead to the
diseases of Irp2−/− mice (LaVaute et al., 2001; Cooperman et al.,
2005; Galy et al., 2005; Ferring-Appel et al., 2009; Jeong et al., 2011;
Ghosh et al., 2013). IRP1 expression is very high relative to IRP2
in the kidneys and lung, whereas IRP2 expression is very high in
the brain, which is consistent with the symptoms of Irp1−/− and
Irp2−/− mice in affected tissues, suggesting that the differences
in the phenotypes of Irp1−/− and Irp2−/− mice are most likely
caused by differences in the cell-speciﬁc expression of these two
proteins (Figures 1 and 2; Meyron-Holtz et al., 2004; Ghosh et al.,
2008, 2013). Nevertheless, in addition to the 44 targets shared by
both IRP1 and IRP2, microarray analysis of IRP-binding tran-
scripts also identiﬁed 101 potential IRP1-speciﬁc targets and 113
potential IRP2-speciﬁc targets. The contribution of these targets
in the pathogenesis of Irp1−/− and Irp2−/− mice is not clear yet,
and characterization of these IRP1- or IRP2- speciﬁc targets could
shed new light on the unique functions of IRP1 and IRP2 in iron
metabolism and development. In addition to the different expres-
sion proﬁles of IRP1 and IRP2 in cells and tissues affected by IRP1
and IRP2 deﬁciency, we have to keep in mind that the expression
proﬁles of other genes including IRP targets as well as other iron
metabolism related genes are also unique in each of these cell types
and tissues. Since IRP targets share the same IRE-binding protein
pool, changes in mRNA expression of each of these IRP targets
will create a unique gene expression context and thereby inevitably
affect the binding of IRPs to other targets, which eventually leads to
the diseases of Irp1 and Irp2 deﬁciency animals. Since there have
been very few attempts to understand iron metabolism in gene
expression context (Hower et al., 2009), application of systemic
biology methodologies probably could elucidate a better picture
of the molecular pathophysiology of disease in the Irp1−/− and
Irp2−/− mice.
CLINICAL IMPLICATIONS
The IRP/IRE system plays an essential role in iron homeosta-
sis, and dysregulation of IRP/IRE system has been reported to
cause many diseases. Mutations in the IRE element of human
L-ferritin disrupt the regulation of IRPs on L-ferritin translation
and result in high ferritin expression and early onset cataracts,
causing hereditary hyperferritinemia cataract syndrome (Ismail
et al., 2006). A mutation in the IRE of human H-ferritin causes
autosomal dominant iron overload (Kato et al., 2001). Disruption
of IRE elements in the mouse FPN1 promoter alters erythro-
poiesis and iron homeostasis, and induces age-dependent loss of
photoreceptors of the retina (Mok et al., 2004a,b; Iacovelli et al.,
2009). These diseases and phenotypes highlight the essential role
of IRP/IRE machinery in iron metabolism and development. The
neurodegeneration and anemia of Irp2−/− mice and the poly-
cythemia and pulmonary hypertension of Irp1−/− mice underline
the essential role of IRP/IRE machinery in regulating cellular and
systemic iron homeostasis, and also suggest that mutations of
IRP1 and IRP2 could underlie some human diseases. Though
patients with diseases attributable to IRP2 mutations have not
been identiﬁed, such patients could be treated by activating IRP1
with stable nitroxide, Tempol, or other nitric oxide sources,
which could compensate for the loss of IRP2 and ameliorate
disease, as demonstrated by alleviation of symptoms in Tempol-
treated Irp2−/− mice (Lipinski et al., 2005; Ghosh et al., 2008;
Jeong et al., 2011).
Polycythemia is a severe disease that stresses the cardiovascular
system and endangers the lives of patients. A routine treatment for
polycythemia is phlebotomy to remove excess blood from patient.
The essential role of IRP1 in regulating HIF2α translation, as
displayed by Irp1−/− mice, suggests that activation of IRP1 by
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Tempol ornitric oxide could repressHIF2α translation and thereby
decrease EPO expression and reduce RBC production. Activation
of IRP1 could be a therapeutic strategy to treat Chuvash poly-
cythemia patients. Erythropoiesis-stimulating agents have been
widely used to treat anemia of chronic diseases, and the sig-
niﬁcant role of IRP1 in repressing HIF2α and EPO production
suggests that inhibiting the interaction between IRP1 and HIF2α
with small molecules could increase HIF2α translation and up-
regulate endogenous EPO levels (Zimmer et al., 2008). Phenotypes
of Irp1−/− mice also suggest that IRP1 mutations could cause
idiopathic polycythemia and pulmonary hypertension in some
patients, and IRP1 should be screened as a candidate disease gene
in these patients. Irp1−/− mice provide a novel mouse model for
pulmonary hypertension, cardiac hypertrophy and aneurysm, and
investigations of this model will provide insights into the molecu-
lar mechanisms of these diseases. Iron deﬁciency anemia is one of
themost common diseases worldwide. The translational derepres-
sion of HIF2α and subsequent increase of EPO levels in Irp1−/−
mice prove that IRP1 plays a critical role in balancing erythro-
poiesis and systemic ironhomeostasis during irondeﬁciency; these
observations explain why the ﬁrst manifestation of iron deﬁciency
is usually anemia.
FUTURE DIRECTIONS
The phenotypes of Irp1−/− and Irp2−/− mice provide compelling
evidence for the essential role of the IRP/IRE system in systemic
iron homeostasis and physiology, suggesting that IRP1 or IRP2
mutations could cause human diseases similar to those discov-
ered in animal models. Screening human patients and identifying
IRP1 or IRP2 mutations could deepen our understanding of their
roles in human iron metabolism. Irp1−/− mice on low iron diet
died from peritoneal hemorrhage, and the physiological function
of IRP1 in the pulmonary and cardiovascular system is not clear
yet. Low iron treatment exacerbates the polycythemia but not pul-
monary hypertension, and the molecular mechanism remains to
be elucidated. Pharmacological activation of IRP1 could be a ther-
apeutic strategy to treat Chuvash polycythemia and pulmonary
hypertension, and inhibition of the interaction between IRP1
and HIF2α could increase EPO production and potentially treat
anemia, and thus modulations of IRP1 activity should be inves-
tigated further. As IRP1 is a bifunctional enzyme, Irp1−/− mice
lose both the IRE-binding activity and cytosolic aconitase activ-
ity, and the contribution and signiﬁcance of cytosolic aconitase
activity of IRP1 in vivo merits further investigation. Microarray
analysis of IRP1- and IRP2- associated mRNAs identiﬁed 35 novel
mRNAs that can bind both IRP1 and IRP2, as well as mRNAs bind
exclusively to either IRP1 or IRP2, and experimental analysis and
characterization of those mRNAs could advance our understand-
ing of the function of IRP/IRE system in systemic ironmetabolism
(Sanchez et al., 2011).
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